Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales

Key Takeaways Alkermes plc (ALKS) reported earnings from continuing operations of 52 cents per share for the second quarter of 2025, which beat the Zacks Consensus Estimate of 41 cents. The company registered earnings of 53 cents per share in the year-ago quarter. Alkermes' total revenues of $390.7 million in the second quarter decreased 2.1% from the year-ago quarter due to lower manufacturing and royalty revenues. The top line, however, comprehensively beat the Zacks Consensus Estimate of $339 million. Ye ...